TY - JOUR
T1 - Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma
AU - Spurgeon, Stephen E.
AU - Pindyck, Talia
AU - Okada, Craig
AU - Chen, Yiyi
AU - Chen, Zunqiu
AU - Mater, Elana
AU - Abbi, Kamal
AU - Epner, Elliot M.
PY - 2011/8
Y1 - 2011/8
N2 - Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma that is incurable with standard chemotherapy. There is no consensus on the best initial therapy, especially for elderly patients, who are not candidates for aggressive treatment approaches. Current National Comprehensive Cancer Network (NCCN) treatment guidelines include rituximab (R) plus cladribine for the initial treatment of MCL. However, few data are available to substantiate this recommendation. Therefore, to further define the role of R-cladribine for the initial treatment of MCL, we performed a retrospective chart review of 31 patients with MCL (median age, 67) treated with R-cladribine. The majority of responding patients also received R maintenance. The overall response rate was 87%, with 61% of patients achieving a complete remission (CR/CRu). The estimated median follow-up was 32.5 months, median PFS was 37.5 months, and median OS was 85.2 months. One of 19 (5.3%) subjects in CR/CRu relapsed (median follow-up of 23 months). CR/CRu was associated with improved survival (p < 0.0001), while a high mantle cell international prognostic index (MIPI) was associated with worse survival (p = 0.05). There was one toxic death (neutropenic pseudomonal sepsis) related to treatment. R-cladribine is an effective therapy for previously untreated MCL, and these results validate the use of R-cladribine for the initial treatment of MCL.
AB - Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma that is incurable with standard chemotherapy. There is no consensus on the best initial therapy, especially for elderly patients, who are not candidates for aggressive treatment approaches. Current National Comprehensive Cancer Network (NCCN) treatment guidelines include rituximab (R) plus cladribine for the initial treatment of MCL. However, few data are available to substantiate this recommendation. Therefore, to further define the role of R-cladribine for the initial treatment of MCL, we performed a retrospective chart review of 31 patients with MCL (median age, 67) treated with R-cladribine. The majority of responding patients also received R maintenance. The overall response rate was 87%, with 61% of patients achieving a complete remission (CR/CRu). The estimated median follow-up was 32.5 months, median PFS was 37.5 months, and median OS was 85.2 months. One of 19 (5.3%) subjects in CR/CRu relapsed (median follow-up of 23 months). CR/CRu was associated with improved survival (p < 0.0001), while a high mantle cell international prognostic index (MIPI) was associated with worse survival (p = 0.05). There was one toxic death (neutropenic pseudomonal sepsis) related to treatment. R-cladribine is an effective therapy for previously untreated MCL, and these results validate the use of R-cladribine for the initial treatment of MCL.
KW - Mantle cell lymphoma
KW - cladribine
KW - response
KW - rituximab
UR - http://www.scopus.com/inward/record.url?scp=79960400013&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960400013&partnerID=8YFLogxK
U2 - 10.3109/10428194.2011.575489
DO - 10.3109/10428194.2011.575489
M3 - Article
C2 - 21623691
AN - SCOPUS:79960400013
SN - 1042-8194
VL - 52
SP - 1488
EP - 1494
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 8
ER -